Powering the RPT Revolution
Radiopharmaceutical theranostics is transforming cancer treatment. RPT Labworks is positioned to capture significant value as the essential preclinical partner for this rapidly growing market.
The Market Opportunity
Radiopharmaceutical theranostics represents one of the most exciting frontiers in oncology. The convergence of imaging diagnostics and targeted therapy is creating unprecedented opportunities.
Market GrowthMarket Growth
The global radiopharmaceutical market is projected to reach $3.56B by 2029, driven by breakthrough therapies and expanded clinical applications.
Clinical SuccessClinical Success
Pluvicto generated $1.4B in 2024 sales alone. With 34+ Phase 3 trials active, the pipeline of approved RPTs is expanding rapidly.
Pharma InvestmentPharma Investment
Major pharmaceutical companies are investing billions in radiopharmaceutical programs through acquisitions, partnerships, and internal R&D.
Unmet NeedUnmet Need
There's a critical shortage of preclinical CROs with radiopharmaceutical expertise, creating significant demand for specialized services.
Key Market Milestones
Why RPT Labworks?
We're uniquely positioned to capture the growing demand for specialized radiopharmaceutical preclinical services.
Deep ExpertiseDeep Expertise
Our leadership team brings decades of combined experience in nuclear medicine, molecular imaging, cancer biology, and medical physics.
Full-Service CapabilitiesFull-Service Capabilities
End-to-end services from consulting and radiochemistry through in vivo imaging and dosimetry—all under one roof.
Speed to ResultsSpeed to Results
Integrated workflows and dedicated teams deliver comprehensive study results in 2-4 weeks, not months.
Radionuclide AgnosticRadionuclide Agnostic
Equipped to handle both imaging and therapeutic radionuclides, from common isotopes to emerging alpha emitters.
Strategic LocationStrategic Location
Located in Madison, WI—a thriving biotech hub with strong academic partnerships and isotope supply chains.
Client-FocusedClient-Focused
Flexible engagement models adapt to your program needs, timeline, and budget. We're partners, not just vendors.
Partner With Us on the RPT Journey
We're seeking strategic partners who share our vision of accelerating radiopharmaceutical development. Let's discuss how we can create value together.
Investor Relations
For media inquiries and press information, please contact us at the email above.